KLISBio

KLISBio is a clinical-stage regenerative medicine and medtech company based in Milan, Italy. The company specializes in developing innovative technology platforms using natural silk fibroin from Bombyx mori silk. By combining traditional silk knowledge with advanced scientific expertise, KLISBio creates highly purified, biocompatible materials suitable for various biomedical applications. The core technology of KLISBio utilizes the unique properties of silk fibroin, which is fully biocompatible and promotes cell proliferation and tissue regeneration. The company is focused on developing implantable regenerative medicine products for orthopedic and vascular markets, including solutions for peripheral nerve repair, vascular grafts, bone graft substitutes, and tendon and ligament repair. Their products aim to enhance tissue regeneration and improve surgical outcomes, addressing conditions such as nerve injuries and bone defects. KLISBio is committed to healthcare innovation and collaborates with early adopters to advance its regenerative medicine solutions. The company positions itself as a leader in the restorative surgical market by offering versatile materials backed by robust scientific research.

• Employees 22
• Founded 2014
• Total Funding $7901640